Purpose: Mortality data within the Sentinel Death Tables remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.
| INTRODUCTION
The 2007 Food and Drug Administration Amendments Act required the Food and Drug Administration (FDA) to develop capabilities to monitor the safety of approved medical products using electronic health-care databases. 1 Today, having progressed through initial development and pilot stages, Sentinel's postmarketing safety surveillance capabilities help inform FDA regulatory policy. Meanwhile, FDA continues to support development and expansion of the Sentinel System. 2 Significant efforts have been dedicated to developing methods to identify selected health outcomes in Sentinel. [3] [4] [5] However, although the Sentinel Common Data Model includes the Death and
Cause of Death Tables, overall and cause-specific mortality outcomes remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.
Clinical trials are designed to detect efficacy but are often not powered to identify rare adverse events, such as death. 6 Mortality from a specific cause, such as suicide, is even more difficult to study.
Even pooled trial data may have too few suicide events 7 or be insufficiently powered to detect differences between treatment groups, 8 even among high-risk populations. Consequently, observational studies are often necessary to assess drug effects on mortality.
We evaluated the feasibility of using all-cause and cause-specific mortality as outcomes for pharmacoepidemiological study in the Sentinel Distributed Database. We compared crude estimates of rates and trends of overall mortality and suicide among participating Sentinel data partners to national estimates. Our primary objective was to determine if the data contained sufficient events to power postmarketing safety studies.
| METHODS
The Sentinel Distributed Database comprises the electronic health data from participating health plans or medical delivery systems. These data partners periodically convert their data into the Sentinel Common Data Model. 9, 10 This allows the data partners to run standardized analyses while maintaining local control of their data resources. A list of all current data partners may be found at the Sentinel website. We performed a sample size analysis to estimate the number of participants needed to measure associations with overall and causespecific mortality. We calculated separate estimates for a range of hazard ratios (HRs): 1.25, 1.5, 2, and 3 with 80% statistical power.
Our sample size calculations assumed a Cox proportional hazard model, 3 years of average follow-up, 20% loss to follow-up per year, 1:1 matching, and the mean mortality rate observed during the study period for each cause of death. These specifications were intended to represent typical Sentinel cohort characteristics.
| RESULTS
During the study period, we identified 479 694 deaths, including 5811 suicides, during 67.6 million person-years of follow-up. Nationally, 22 130 096 deaths, including 323 666 suicides, were recorded during this time span. The pooled mean death rate observed within participating data partners was 709 per 100 000 person-years, compared with 810 deaths per 100 000 person-years nationally ( Table 1 ). The mean suicide rate observed among data partners, 8.6 per 100 000
person-years, was also lower than the national estimate of 11.8 per 100 000 person-years. The overall mean proportional mortality from
KEY POINTS
• This was the first descriptive study to characterize mortality outcomes in Sentinel.
• We observed 479 694 deaths, including 5811 suicides, during 68 million person-years of follow-up.
• All-cause mortality appears well powered for use as a safety outcome for common drugs that have been on the market for several years.
• Cause-specific mortality outcomes may be adequately powered in certain circumstances.
• Further investigation into the quality of the Sentinel death data is needed.
suicide (1.2%) among data partners was also lower compared with 1.5% nationally. While age-and sex-specific mortality was consistently lower within Sentinel, compared with the general United States, proportional mortality from suicide was more similar for most age and sex subgroups, except for men aged 25 to 50, who had much lower proportional mortality within Sentinel. National trends for overall mortality ( Figure 1 ) and proportional mortality for suicide ( Figure 2 ) during the study period were reflected within data partner-level data (not shown). Both data sources showed a trend of decreasing mortality rates early during the study period followed by a slight increase in the last 2 to 3 years, and both showed an increasing trend for proportional mortality from suicide for the duration of the study period.
Available sample sizes and rates for all-cause mortality and 10 leading causes of death among the participating data partners are displayed in Table 2 . Overall, we found all-cause mortality and common causes of death may be well-powered for Cox analysis for HRs as low as 1.25, assuming that the exposure is not rare. Otherwise, using the prespecified criteria for this power analysis, well-powered studies would require common exposures or strong associations. A study with overall mortality as the primary outcome would require 16 442 exposed to detect a HR of 1.25 and 460 exposed to find an HR of 3. Conversely, a study with completed suicide as the outcome would require a large sample size (>1.3 million exposed) to find a HR of 1.25, although strong associations (HR = 2+) may still be possible for studies with common exposures.
| DISCUSSION
Among participating data partners, we identified approximately 53 000 deaths and 650 suicides annually from 2004 to 2012. Our power analysis showed that overall mortality and leading causes of death may be feasible outcomes for many studies, while less common causes of death may require large sample sizes or strong associations to be feasible for analysis in Sentinel.
We did not directly assess the validity of the death data used for this analysis. However, trends for death rates and proportional mortality from suicide were similar between participating Sentinel data Research, suggesting consistent ascertainment over the study period.
We observed lower mortality and suicide rates among the participating data partners compared with the general US population. Previous studies have consistently found reduced risk of death among individuals with medical coverage [15] [16] [17] [18] and reduced risk of suicide among those with access to mental health services. [19] [20] [21] The lower estimated rates of death among participating data partners, compared with national estimates, may also be partially explained by a younger, future studies might involve populations with higher or lower rates.
Of the leading causes of death, we only examined suicide in detail.
It is possible other causes of death did not follow national trends or may not be consistently ascertained within Sentinel, as we observed with suicide. Finally, the age groups we used for our analysis were too broad for calculation of accurate standardized mortality rates, which would have allowed a more precise quantitative comparison with mortality rates in the US population.
Overall, we found participating data partners' all-cause mortality data appeared to provide adequate power for mortality as a safety outcome with commonly used medical products marketed for several years. Cause-specific mortality outcomes may be adequately powered for study within Sentinel, depending on the prevalence of the specific exposure and outcome under study. However, further expansion and refinement of the Death and Cause of Death tables may be required, such as refining the capability to identify underlying cause of death.
This was the first study to characterize mortality outcomes in the Sentinel Distributed Database. As experience with the Sentinel database accumulates, further investigation into the quality of the mortality data in Sentinel Death and Cause of Death Tables should help to clarify its appropriateness for pharmacoepidemiological studies.
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